Vicore Pharma’s Phase 2b ASPIRE trial clears futility analysis and stays on track for mid‑2027 readout
Vicore Pharma announced that the independent Data Monitoring Committee recommended continuation of its Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis after a pre‑planned futility analysis. The trial, fully enrolled with 378 patients, remains scheduled to deliver 52‑week topline results in mid‑2027. Management said the company’s cash runway extends into the second half of 2028, covering the readout period.
Why it matters
The continuation means no delay to the expected mid‑2027 efficacy readout, preserving the timeline for potential regulatory filing and market impact. The company’s cash runway through H2 2028 ensures funding for the trial’s completion without dilution risk.
Key facts
- 1The trial enrolled 378 patients across more than 100 sites in 14 countries. stocktitan.net
- 2The independent Data Monitoring Committee recommended the trial continue without modification after the futility analysis. stocktitan.net
- 3Topline results from the 52‑week primary endpoint are expected in mid‑2027. stocktitan.net
- 4Vicore’s cash runway extends into the second half of 2028. finanznachrichten.de
- 5The futility analysis used data from approximately the first 100 randomized patients (about 27% of enrolment) and a conditional‑power threshold of 20% to consider stopping the trial. finanznachrichten.de
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.